101 related articles for article (PubMed ID: 9089710)
1. Preparation and biodistribution of copper-67-labeled porphyrins and porphyrin-A6H immunoconjugates.
Bhalgat MK; Roberts JC; Mercer-Smith JA; Knotts BD; Vessella RL; Lavallee DK
Nucl Med Biol; 1997 Feb; 24(2):179-85. PubMed ID: 9089710
[TBL] [Abstract][Full Text] [Related]
2. Labeling antibodies with copper radionuclides using N-4-nitrobenzyl-5-(4-carboxyphenyl)-10,15,20-tris(4-sulfophenyl) porphine.
Roberts JC; Newmyer SL; Mercer-Smith JA; Schreyer SA; Lavallee DK
Int J Rad Appl Instrum A; 1989; 40(9):775-81. PubMed ID: 2559066
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2.
Wilbur DS; Vessella RL; Stray JE; Goffe DK; Blouke KA; Atcher RW
Nucl Med Biol; 1993 Nov; 20(8):917-27. PubMed ID: 8298571
[TBL] [Abstract][Full Text] [Related]
4. The biodistribution of radiocopper-labeled compounds.
Mercer-Smith JA; Cole DA; Roberts JC; Lewis D; Behr MJ; Lavallee DK
Adv Exp Med Biol; 1989; 258():103-21. PubMed ID: 2626980
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and radioimmunoscintigraphy studies of renal cell carcinoma using tumor-preferential monoclonal antibodies and F(ab')2 fragments.
Chiou RK
J Urol; 1989 Dec; 142(6):1584-8. PubMed ID: 2585642
[TBL] [Abstract][Full Text] [Related]
6. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts.
Sands H; Jones PL; Shah SA; Palme D; Vessella RL; Gallagher BM
Cancer Res; 1988 Jan; 48(1):188-93. PubMed ID: 3334993
[TBL] [Abstract][Full Text] [Related]
7. Localization of human renal cell carcinoma xenografts with a tumor-preferential monoclonal antibody.
Chiou RK; Vessella RL; Elson MK; Clayman RV; Gonzalez-Campoy JM; Klicka MJ; Shafer RB; Lange PH
Cancer Res; 1985 Dec; 45(12 Pt 1):6140-6. PubMed ID: 2415239
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of copper-67 porphyrin-antibody conjugates.
Roberts JC; Figard SD; Mercer-Smith JA; Svitra ZV; Anderson WL; Lavallee DK
J Immunol Methods; 1987 Dec; 105(2):153-64. PubMed ID: 3693904
[TBL] [Abstract][Full Text] [Related]
9. Tumor localization and therapeutic potential of an antitumor-anti-CD3 heteroconjugate antibody in human renal cell carcinoma xenograft models.
Zhu Z; Ghose T; Lee SH; Fernandez LA; Kerr LA; Donohue JH; McKean DJ
Cancer Lett; 1994 Oct; 86(1):127-34. PubMed ID: 7954349
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled porphyrin vs gallium-67 citrate for the detection of human melanoma in athymic mice.
Maric N; Chan SM; Hoffer PB; Duray P
Int J Rad Appl Instrum B; 1988; 15(5):543-51. PubMed ID: 3254877
[TBL] [Abstract][Full Text] [Related]
11. Preparation and preliminary biological evaluation of a novel 109Pd labeled porphyrin derivative for possible use in targeted tumor therapy.
Chakraborty S; Das T; Banerjee S; Sarma HD; Venkatesh M
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):16-23. PubMed ID: 17372569
[TBL] [Abstract][Full Text] [Related]
12. 109Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a potential agent for targeted tumor therapy.
Das T; Chakraborty S; Sarma HD; Banerjee S
Curr Radiopharm; 2012 Oct; 5(4):340-7. PubMed ID: 22935057
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody-targeted radiotherapy of renal cell carcinoma using a nude mouse model.
Chiou RK; Vessella RL; Limas C; Shafer RB; Elson MK; Arfman EW; Lange PH
Cancer; 1988 May; 61(9):1766-75. PubMed ID: 2451555
[TBL] [Abstract][Full Text] [Related]
14. Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging.
Zimmermann K; Grünberg J; Honer M; Ametamey S; Schubiger PA; Novak-Hofer I
Nucl Med Biol; 2003 May; 30(4):417-27. PubMed ID: 12767399
[TBL] [Abstract][Full Text] [Related]
15. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
17. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
Steffens MG; Oosterwijk E; Kranenborg MH; Manders JM; Debruyne FM; Corstens FH; Boerman OC
J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
[TBL] [Abstract][Full Text] [Related]
19. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
[TBL] [Abstract][Full Text] [Related]
20. Tumor localization of monoclonal antibodies against human renal carcinoma in a xenograft model.
Guha AK; Ghose T; Singh M; Aquino J; Blair AH; Luner SJ; Mammen M
Cancer Lett; 1991 Dec; 61(1):35-43. PubMed ID: 1764696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
